MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Sorrento Therapeutics EV/EBITDA Ratio 2011-2026 | SRNE
Annual EV/EBITDA Ratio Sorrento Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.01 | -15 | -3.81 | -2.41 | 9.33 | -3.88 | -3.36 | -6.51 | -8.38 | -14.5 | -16.6 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.33 | -16.6 | -6.2 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-0.271 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Exelixis
EXEL
|
18.1 | $ 48.7 | - | $ 13.2 B | USA |
 |
Athira Pharma
ATHA
|
-3.66 | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
-0.152 | $ 2.55 | - | $ 71.1 M | USA |
 |
Genmab A/S
GMAB
|
2.7 | $ 27.89 | - | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
-4.81 | $ 0.89 | - | $ 830 K | USA |
 |
Grifols, S.A.
GRFS
|
13.7 | $ 8.41 | - | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
-1.93 | $ 2.5 | - | $ 168 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-363 | $ 76.85 | - | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
4.1 | $ 95.26 | - | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.0315 | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
-21.5 | $ 86.26 | - | $ 7.29 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
19.4 | $ 232.55 | - | $ 4.25 B | USA |
 |
INmune Bio
INMB
|
-3.64 | $ 1.52 | - | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
-6.02 | $ 42.14 | - | $ 3.63 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
-21.1 | $ 21.48 | - | $ 3.56 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
2.69 K | $ 110.08 | - | $ 5.53 B | USA |
 |
MannKind Corporation
MNKD
|
34.4 | $ 3.56 | - | $ 1.09 B | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-2.15 | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-43.1 | $ 3.35 | - | $ 5.51 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | Canada |
 |
Matinas BioPharma Holdings
MTNB
|
-8.08 | $ 0.68 | - | $ 3.72 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-4.62 K | $ 41.86 | - | $ 286 B | France |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-1.56 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-1.56 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-316 | $ 24.17 | - | $ 3.08 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
0.298 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-20.4 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | USA |